

Adeno-Associated Virus (AAV) Vectors in Gene Therapy Pipeline 2024: Clinical Trials, FDA, EMA, and PMDA Approvals

Adeno-Associated Virus (AAV) Vectors in Gene Therapy Pipeline

DELHI, DELHI, INDIA, July 1, 2024

/EINPresswire.com/ -- DelveInsight's, "AAV Vectors in Gene Therapy Pipeline Insight 2024" report provides comprehensive insights about 70+ companies and 235+ pipeline drugs in AAV vectors in gene therapy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.



Adeno-Associated Virus (AAV) Vectors in Gene Therapy Pipeline

Request a sample and discover the recent advances in AAV vectors in gene therapy @ [AAV Vectors in Gene Therapy Pipeline Outlook](#)

Key Takeaways from the AAV Vectors in Gene Therapy Pipeline Report

- DelveInsight's Adeno-Associated Virus Vectors in Gene Therapy pipeline report depicts a robust space with 70+ active players working to develop 235+ pipeline therapies for Adeno-Associated Virus Vectors in Gene Therapy treatment.
- The leading companies working in the Adeno-Associated Virus Vectors in Gene Therapy Market include BioMarin Pharmaceutical, Gensight Biologics, PTC therapeutics, Ultragenyx Pharmaceutical, MeiraGTx, Pfizer, Biogen, uniQure, Ultragenyx Pharmaceutical, REGENXBIO, Biogen, Spark therapeutics (Roche), Sarepta therapeutics, Neurophth Therapeutics, LYSOGENE, Gyroscope Therapeutics, Nanoscope Therapeutics, Homology medicines, Ultragenyx Pharmaceutical, Passage Bio, Freeline therapeutics, Astellas Pharma, Aspa therapeutics, Adrenas Therapeutics, ESTEVE, Sio Gene Therapies, Amicus therapeutics, 4D Molecular therapeutics, Taysha Gene Therapies, Atsena Therapeutics, BioMarin Pharmaceutical, Abeona Therapeutics,

REGENXBIO, uniQure, Taysha Gene Therapies, Asklepios BioPharmaceutical, Sarepta Therapeutics, Abeona Therapeutics, Forge Biologics, Sangamo therapeutics, and others.

- Promising Adeno-Associated Virus Vectors in Gene Therapy Pipeline Therapies in the various stages of development include Valoctocogene Roxaparvovec, AAV - CNGB3, SB-525 (PF-07055480), AAV2/5-RPGR, BMN 307, GC301, rAAV-Olig001-ASPA, and others.
- May 2024:- UniQure Biopharma B.V.- A Phase Ib/II Randomized, Double-Blind Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Doses of Striataly-Administered rAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Therapy (AMT 130) in Early Manifest Huntington's Disease. This is the second study of AMT-130 in patients with early manifest HD and is designed as part of an integrated two-study phase I/II program under a single data safety monitoring board (DSMB) with staggered enrollment based upon continued demonstration of safety of AMT-130 administration.
- May 2024:- Tenaya Therapeutics- Seroprevalence Study of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC). This is a multicenter, non-interventional study to observe the natural progression of the disease and to study the prevalence of pre-existing antibodies to AAV9 used for gene therapy in a population of patients with PKP2 gene-associated ARVC. Participation from all patients is encouraged regardless of interest in or eligibility for gene therapy.

Learn more about the AAV vectors for gene therapy in clinical trials @ [New AAV Vectors for Gene Therapy Drugs](#)

AAV vectors in Gene Therapy Emerging Drugs

- GS010: Gensight Biologics
- Valoctocogene roxaparvovec: BioMarin Pharmaceutical
- DTX401: Ultragenyx Pharmaceutical
- AAV5-RPGR: MeiraGTx
- Timrepigene emparvovec: Biogen
- AMT 061: UniQure
- RGX-314: REGENXBIO
- SPK-8011: Spark Therapeutics
- NFS-01: Neurophth
- GT 005: Gyroscope Therapeutics

Discover more about AAV vectors in gene therapy in development @ [AAV Vectors in Gene Therapy Clinical Trials](#)

AAV Vectors in Gene Therapy: Therapeutic Assessment

There are approx. 70+ key Adeno-Associated Virus (AAV) Vectors in Gene Therapy companies developing Adeno-Associated Virus (AAV) Vectors in Gene Therapy therapies. The Adeno-Associated Virus (AAV) Vectors in Gene Therapy companies that have their AAV vectors in gene therapy drug candidates in the most advanced stage, i.e. Preregistration include BioMarin

Pharmaceutical.

To know more about AAV vectors in gene therapy, visit @ AAV Vector Technology Segmentation

Adeno-Associated Vector Companies

BioMarin Pharmaceutical, Gensight Biologics, PTC therapeutics, Ultragenyx Pharmaceutical, MeiraGTx, Pfizer, Biogen, uniQure, Ultragenyx Pharmaceutical, REGENXBIO, Biogen, Spark therapeutics (Roche), Sarepta therapeutics, Neurophth Therapeutics, LYSOGENE, Gyroscope Therapeutics, Nanoscope Therapeutics, Homology medicines, Ultragenyx Pharmaceutical, Passage Bio, Freeline therapeutics, Astellas Pharma, Aspa therapeutics, Adrenas Therapeutics, ESTEVE, Sio Gene Therapies, Amicus therapeutics, 4D Molecular therapeutics, Taysha Gene Therapies, Atsena Therapeutics, BioMarin Pharmaceutical, Abeona Therapeutics, REGENXBIO, uniQure, Taysha Gene Therapies, Asklepios BioPharmaceutical, Sarepta Therapeutics, Abeona Therapeutics, Forge Biologics, Sangamo therapeutics, and others

Adeno-Associated Vector pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

- Intracerebral
- Intracerebroventricular
- Intracisternal
- Intramuscular
- Intraocular
- Intrapancreatic
- Intrastratial
- Intrathecal
- Intravenous
- Intravitreous
- Introvitinreous
- Oral
- Parenteral
- Retinal
- Intra-arterial
- Molecule Type

Adeno-Associated Vector Products have been categorized under various Molecule types such as

- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type

For further information on the AAV vectors in gene therapy pipeline therapeutics, reach out @ AAV Vector Gene Therapy Products Development- https://www.delveinsight.com/sample-request/aden-associated-virus-aav-vectors-in-gene-therapy-pipeline-insight?utm_source=einpresswire&utm_medium=promotion&utm_campaign=ypr

Scope of the Adeno-Associated Virus (AAV) Vectors in Gene Therapy Pipeline Report

- Coverage- Global
- Adeno-Associated Virus Vectors in Gene Therapy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Adeno-Associated Virus Vectors in Gene Therapy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Adeno-Associated Virus Vectors in Gene Therapy Companies- BioMarin Pharmaceutical, Gensight Biologics, PTC therapeutics, Ultragenyx Pharmaceutical, MeiraGTx, Pfizer, Biogen, uniQure, Pfizer, Ultragenyx Pharmaceutical, REGENXBIO, Biogen, Spark therapeutics (Roche), Sarepta therapeutics, Neurophth Therapeutics, LYSOGENE, Gyroscope Therapeutics, Nanoscope Therapeutics, Homology medicines, Ultragenyx Pharmaceutical, Passage Bio, Freeline therapeutics, Astellas Pharma, Aspa therapeutics, Adrenas Therapeutics, ESTEVE, Sio Gene Therapies, Amicus therapeutics, 4D Molecular therapeutics, Taysha Gene Therapies, Atsena Therapeutics, BioMarin Pharmaceutical, Abeona Therapeutics, and others.
- Adeno-Associated Virus Vectors in Gene Therapy Pipeline Therapies- Valoctocogene Roxaparvovec, AAV - CNGB3, SB-525 (PF-07055480), AAV2/5-RPGR, BMN 307, GC301, rAAV-Olig001-ASPA, and others.

Discover more about Adeno-Associated Virus (AAV) Vectors in Gene Therapy Drugs in development @ Adeno-Associated Virus (AAV) Vectors in Gene Therapy Unmet Needs- https://www.delveinsight.com/sample-request/aden-associated-virus-aav-vectors-in-gene-therapy-pipeline-insight?utm_source=einpresswire&utm_medium=promotion&utm_campaign=ypr

Table of Content

1. Introduction
2. Executive Summary
3. AAV vectors in gene therapy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Preregistration)
7. Valoctocogene roxaparvovec: BioMarin Pharmaceutical
8. Drug profiles in the detailed report.....
9. Late Stage Products (Phase III)
10. DTX401: Ultragenyx Pharmaceutical
11. Drug profiles in the detailed report.....
12. Mid Stage Products (Phase II)

13. GT 005: Gyroscope Therapeutics
14. Drug profiles in the detailed report.....
15. Early stage products (Phase I/II)
16. Drug profiles in the detailed report.....
17. Early Stage Products (Phase I)
18. HMI-203: Homology Medicine
19. Drug profiles in the detailed report.....
20. Preclinical stage products
21. AXV101: Axovia Therapeutics
22. Drug profiles in the detailed report.....
23. Discovery stage products
24. DINA-002: DiNAQOR
25. Drug profiles in the detailed report.....
26. Inactive Products
27. AAV vectors in gene therapy Key Companies
28. AAV vectors in gene therapy Key Products
29. AAV vectors in gene therapy- Unmet Needs
30. AAV vectors in gene therapy- Market Drivers and Barriers
31. AAV vectors in gene therapy- Future Perspectives and Conclusion
32. AAV vectors in gene therapy Analyst Views
33. AAV vectors in gene therapy Key Companies
34. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Yash Bhardwaj
DelveInsight
+91 9650213330
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/724279463>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.